Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Other Non-Current Liabilities (2018 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Other Non-Current Liabilities over the past 13 years, most recently at $25.0 million for Q2 2025.

  • For Q2 2025, Other Non-Current Liabilities rose 107.21% year-over-year to $25.0 million; the TTM value through May 2025 reached $25.0 million, up 107.21%, while the annual FY2025 figure was $25.0 million, 107.21% up from the prior year.
  • Other Non-Current Liabilities for Q2 2025 was $25.0 million at Lifecore Biomedical, Inc. \De\, up from $23.9 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $64.9 million in Q2 2023 and troughed at $183000.0 in Q4 2023.
  • A 5-year average of $11.1 million and a median of $2.9 million in 2021 define the central range for Other Non-Current Liabilities.
  • Biggest five-year swings in Other Non-Current Liabilities: crashed 91.62% in 2022 and later surged 12632.24% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $1.9 million in 2021, then crashed by 89.6% to $201000.0 in 2022, then dropped by 8.96% to $183000.0 in 2023, then surged by 12632.24% to $23.3 million in 2024, then increased by 7.26% to $25.0 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for LFCR at $25.0 million in Q2 2025, $23.9 million in Q1 2025, and $23.3 million in Q4 2024.